The Latest in Non-Hodgkin Lymphoma Hub

FDA approves pembrolizumab for relapsed/refractory PMBCL

June 14, 2018

Aggressive Lymphomas

FDA grants regular approval to venetoclax for CLL/SLL

June 8, 2018

Indolent Lymphoma

Venetoclax plus ibrutinib yields encouraging MRD results in first-line CLL

June 8, 2018

Indolent Lymphoma

Chemo-free regimen appears viable in previously untreated FL

June 7, 2018

Aggressive Lymphomas

Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL

June 6, 2018

Aggressive Lymphomas

Ibrutinib plus rituximab amped PFS in Waldenström’s

June 1, 2018

Indolent Lymphoma

Overcoming TP53 mutation proves difficult in MCL

June 1, 2018

Aggressive Lymphomas

Older CLL and NHL patients are more vulnerable to toxicities

May 23, 2018

Indolent Lymphoma

Physical inactivity linked to lymphoma risk

May 18, 2018

Indolent Lymphoma

Pediatric cancers are on the rise

May 17, 2018

Aggressive Lymphomas

Adding bortezomib does not improve MCL outcomes

May 16, 2018

Aggressive Lymphomas

Study: No link between non-Hodgkin lymphoma and Q fever

May 15, 2018

Aggressive Lymphomas

5-year data show deepening response with ibrutinib in CLL

May 11, 2018

Indolent Lymphoma

In young MCL patients, optimal treatment may vary

May 4, 2018

Indolent Lymphoma

Early results favor combo IL-15/anti-CD20 in indolent NHL

May 3, 2018

Indolent Lymphoma